CL
CLYM.US Climb Bio Inc
- Market cap
- USD 609M
- P/E
- -
- P/B
- 2.80x
- ROE
- -24.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is CLYM.US undervalued?
Graham numberThe Graham number of Climb Bio Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Climb Bio Inc fundamental analysis
No fundamental analysis for Climb Bio Inc yet.
Climb Bio Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Climb Bio Inc
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy and immune thrombocytopenia; and Phase 1b clinical trial in…
Full company profileClimb Bio Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Climb Bio Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | - | - | - | - | - | - | -97.0K | - |
| Operating Income | -7.45M | -20.9M | -35.7M | -45.1M | -40.3M | -82.0M | -67.9M | -63.3M |
| EBITDA | -4.70M | -11.8M | -47.5M | -45.2M | -35.1M | -30.4M | -59.8M | -61.2M |
| Net Income | -6.55M | -20.7M | -47.5M | -45.2M | -35.1M | -73.9M | -59.9M | -55.7M |
| EPS | -0.56 | -1.77 | -3.87 | -1.72 | -1.30 | -1.53 | -0.88 | -0.70 |
| Balance Sheet | ||||||||
| Total Assets | 21.4M | 24.6M | 173M | 135M | 110M | 217M | 168M | 237M |
| Total Liabilities | 783K | 3.06M | 6.04M | 6.28M | 2.87M | 5.31M | 7.27M | 8.51M |
| Shareholders' Equity | 20.6M | 21.6M | 167M | 129M | 108M | 212M | 160M | 228M |
| Cash & Short-term Investments | 21.2M | 20.5M | 136M | 124M | 107M | 151M | 101M | 205M |
| Total Debt | - | - | - | 480K | 349K | 532K | 541K | 1.07M |
| Cash Flow | ||||||||
| Operating Cash Flow | -5.01M | -14.1M | -36.1M | -37.4M | -20.6M | -15.6M | -54.4M | -49.2M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 186K | 1.44M |
| Free Cash Flow | -5.01M | -14.1M | -36.1M | -37.4M | -20.6M | -15.6M | -54.5M | -50.7M |
| Ratios | ||||||||
| ROE | -31.8% | -95.8% | -28.4% | -35.2% | -32.6% | -34.9% | -37.3% | -24.4% |
| ROA | -30.6% | -83.9% | -27.4% | -33.5% | -31.8% | -34.0% | -35.7% | -23.6% |
| Debt to Equity | - | - | - | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Climb Bio Inc dividends
Climb Bio Inc has not paid dividends in the last 7 fiscal years.
Who owns Climb Bio Inc
- Insiders 0.18%
- Institutions 99.83%
- Public & others 0.00%
- Shares outstanding 58.7M
- Free float 36.9M
Top funds holding CLYM.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Small Cap Growth | 1.88M | 3.21% | 0.00% | Aug 2026 |
| T. Rowe Price Health Sciences | 1.86M | 3.17% | 0.00% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 1.86M | 3.16% | +35.96% | Sep 2026 |
| Fidelity Stock Selector Small Cap | 1.53M | 2.60% | 0.00% | Aug 2026 |
| State Street® SPDR® S&P® Biotech ETF | 1.15M | 1.97% | +2.69% | Oct 2026 |
| Fidelity Advisor Biotechnology I | 996K | 1.70% | 0.00% | Sep 2026 |
| Fidelity Small Cap Growth K6 | 978K | 1.66% | 0.00% | Aug 2026 |
| iShares Russell 2000 ETF | 933K | 1.59% | 0.00% | Oct 2026 |
| Fidelity Series Small Cap Opps | 876K | 1.49% | 0.00% | Aug 2026 |
| Columbia Small Cap Growth Inst | 807K | 1.37% | +50.04% | Sep 2026 |
| Fidelity Select Biotechnology | 721K | 1.23% | 0.00% | Aug 2026 |
| Strategic Advisers Fidelity US TtlStk | 479K | 0.81% | 0.00% | Sep 2026 |
| Fidelity Select Health Care | 449K | 0.76% | +2.65% | Aug 2026 |
| Fidelity Small Cap Index | 386K | 0.66% | 0.00% | Aug 2026 |
| Fidelity Advisor Health Care I | 295K | 0.50% | +34.58% | Sep 2026 |
| Fidelity Select Pharmaceuticals Port | 292K | 0.50% | +14.45% | Sep 2026 |
| Vanguard US Momentum Factor ETF | 247K | 0.42% | 0.00% | Sep 2026 |
| Vanguard Russell 2000 ETF | 215K | 0.37% | +6.07% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 210K | 0.36% | +0.23% | Oct 2026 |
| iShares Russell 2000 Value ETF | 196K | 0.33% | 0.00% | Oct 2026 |
Top institutions holding CLYM.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| RA Capital Management, LLC | 11.3M | 19.24% | 0.00% | Jun 2026 |
| FMR Inc | 6.79M | 11.56% | +106,049.19% | Jun 2026 |
| UBS Group AG | 3.40M | 5.80% | +3,861.68% | Jun 2026 |
| BRAIDWELL LP | 2.80M | 4.76% | +82.87% | Jun 2026 |
| Adage Capital Partners Gp LLC | 2.51M | 4.27% | 0.00% | Jun 2026 |
| BlackRock Inc | 2.35M | 4.01% | +486.30% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 2.13M | 3.62% | +10.97% | Jun 2026 |
| Cormorant Asset Management, LLC | 2.11M | 3.59% | 0.00% | Jun 2026 |
| Frontier Capital Management CO Inc | 1.94M | 3.30% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 1.70M | 2.89% | +44.12% | Jun 2026 |
| Woodline Partners LP | 1.58M | 2.69% | 0.00% | Jun 2026 |
| Citadel Advisors Llc | 1.30M | 2.21% | +275.50% | Jun 2026 |
| Redmile Group, LLC | 1.23M | 2.09% | 0.00% | Jun 2026 |
| Great Point Partners LLC | 1.00M | 1.70% | -25.04% | Jun 2026 |
| Affinity Asset Advisors, LLC | 972K | 1.65% | +38.86% | Jun 2026 |
| Millennium Management LLC | 908K | 1.55% | -28.84% | Jun 2026 |
| ADAR1 Capital Management LLC | 823K | 1.40% | +37.64% | Jun 2026 |
| Driehaus Capital Management LLC | 790K | 1.35% | +31.46% | Jun 2026 |
| Geode Capital Management, LLC | 782K | 1.33% | +149.90% | Jun 2026 |
| StemPoint Capital LP | 743K | 1.26% | 0.00% | Jun 2026 |
Climb Bio Inc company profile
- Company name
- Climb Bio Inc
- Ticker
- CLYM.US
- Exchange
- USA Stocks
- Listed since
- Aug 10, 2021
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 28
- Fiscal year end
- December
- Address
- 20 William Street, Wellesley Hills, MA, United States, 02481
- Phone
- 866 857 2596
- Website
- climbbio.com
About Climb Bio Inc
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy and immune thrombocytopenia; and Phase 1b clinical trial indicated for the systemic lupus erythematosus. In addition, the company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobin A nephropathy (IgAN) and other B-cell mediated diseases. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wellesley Hills, Massachusetts.
Climb Bio Inc management
7- Dr. Aoife M. Brennan BAO, BCh, M.D., MB, MMScCEO, President & Director · born 1976
- Dr. Susan Altschuller M.B.A., Ph.D.CFO & Principal Accounting Officer · born 1982
- Dr. Perrin Wilson B.S., Ph.D.Chief Business Officer · born 1979
- Mr. Adam VillaSenior Vice President of Technical Operations
- Ms. Chandra Adams J.D.Senior VP, General Counsel & Secretary
- Ms. Ashley JonesSenior Vice President of People & Workforce Strategy
- Dr. Edgar D. Charles M.D., M.Sc.Chief Medical Officer